Abstract
Increased fructose intake from sugar-sweetened beverages and highly processed sweets is a well-recognized risk factor for the development of obesity and its complications. Fructose strongly supports lipogenesis on a normal chow diet by providing both, a substrate for lipid synthesis and activation of lipogenic transcription factors. However, the negative health consequences of dietary sugar are best observed with the concomitant intake of a HFD. Indeed, the most commonly used obesogenic research diets, such as “Western diet”, contain both fructose and a high amount of fat. In spite of its common use, how the combined intake of fructose and fat synergistically supports development of metabolic complications is not fully elucidated. Here we present the preponderance of evidence that fructose consumption decreases oxidation of dietary fat in human and animal studies. We provide a detailed review of the mitochondrial β-oxidation pathway. Fructose affects hepatic activation of fatty acyl-CoAs, decreases acylcarnitine production and impairs the carnitine shuttle. Mechanistically, fructose suppresses transcriptional activity of PPARα and its target CPT1α, the rate limiting enzyme of acylcarnitine production. These effects of fructose may be, in part, mediated by protein acetylation. Acetylation of PGC1α, a co-activator of PPARα and acetylation of CPT1α, in part, account for fructose-impaired acylcarnitine production. Interestingly, metabolic effects of fructose in the liver can be largely overcome by carnitine supplementation. In summary, fructose decreases oxidation of dietary fat in the liver, in part, by impairing acylcarnitine production, offering one explanation for the synergistic effects of these nutrients on the development of metabolic complications, such as NAFLD.
| Original language | English |
|---|---|
| Article number | 109224 |
| Journal | Journal of Nutritional Biochemistry |
| Volume | 114 |
| DOIs | |
| State | Published - Apr 2023 |
Bibliographical note
Publisher Copyright:© 2022 Elsevier Inc.
Funding
This work was also supported by NASPGHAN Foundation Young Investigator Award, Pediatric Scientist Development Program Award (HD000850) and COCVD Pilot and Feasibility Grant (GM127211) awarded to SS. National Institutes of Health grants K01DK128022 and NIH National Center for Advancing Translational Sciences through grant number UL1TR001998 awarded to RNH.
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | K01DK128022 |
| National Center for Advancing Translational Sciences (NCATS) | UL1TR001998 |
| NASPGHAN Foundation | GM127211, HD000850 |
Keywords
- Fatty acid oxidation (FAO)
- Fructose
- Non-alcoholic fatty liver disease (NAFLD)
- Sugar
- Western diet
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Biochemistry
- Molecular Biology
- Nutrition and Dietetics
- Clinical Biochemistry